-
OPERATIONALIZING PATIENT ENGAGEMENT IN RARE DISEASE VALUE RESEARCH LESSONS FROM DISEASE-SPECIFIC USE CASES
Mar 18, 2026, 21:38 PM -
EVALUATING THE QUALITY OF CLINICAL EVIDENCE FOR DIGITAL HEALTH SOLUTIONS ACROSS FIVE THERAPEUTIC AREAS: FINDINGS FROM PHTI ASSESSMENTS
Mar 18, 2026, 21:38 PM -
A HEALTH ECONOMIC AND ENVIRONMENTAL EVALUATION OF SUBCUTANEOUS PERTUZUMAB/TRASTUZUMABVERSUS INTRAVENOUS PERTUZUMAB/TRASTUZUMAB FOR HER2-POSITIVE BREAST CANCER IN DENMARK (HEREAFTER)
Mar 18, 2026, 21:38 PM -
ENHANCING CLINICAL TRIAL ELIGIBILITY CRITERIA DESIGN WITH GENERATIVE ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING
Mar 18, 2026, 21:38 PM -
AVOIDABLE DIRECT COSTS IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) TREATED WITH DAROLUTAMIDE: A REAL-WORLD EVIDENCE FROM A MULTICENTER STUDY IN COLOMBIA
Mar 18, 2026, 21:38 PM -
COPD IN THE UNITED STATES: FACTORS AFFECTING TREATMENT PATTERNS AND UTILIZATION OF PHARMACOTHERAPY
Mar 18, 2026, 21:38 PM -
METHODOLOGICAL INSIGHTS INTO VACCINE HESITANCY RESEARCH IN RESPIRATORY DISEASES IN ADULTS AT-RISK: SYSTEMATIC REVIEW
Mar 18, 2026, 21:38 PM -
DISTINGUISHING AI FROM AUTOMATION IN HEOR: LESSONS FROM OTHER INDUSTRIES
Mar 18, 2026, 21:38 PM -
BRIDGING HER2 TESTING AND TREATMENT: REAL-WORLD EVIDENCE ACROSS 22 SOLID TUMORS
Mar 18, 2026, 21:38 PM -
NEUROLOGIST PREFERENCES FOR NEW MS TREATMENTS: IMPLICATIONS FOR MARKET ACCESS PRIORITIZATION IN THE UNITED STATES AND EUROPE
Mar 18, 2026, 21:38 PM -
TRANSLATION AND PSYCHOMETRIC EVALUATION OF THE YORUBA VERSION OF IBADAN LOW-BACK PAIN DISABILITY QUESTIONNAIRE
Mar 18, 2026, 21:38 PM -
CHARACTERIZING REAL-WORLD DISEASE BURDENS IN CARDIAC AMYLOIDOSIS: A DESCRIPTIVE STUDY ON SOCIAL, ECONOMIC, AND ACCESS-RELATED IMPACTS ON PATIENTS IN GERMANY AND SPAIN
Mar 18, 2026, 21:38 PM -
DISEASE PERCEPTION, QUALITY OF LIFE, AND MENTAL HEALTH OF NEWLY DIAGNOSED AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)-ELIGIBLE MULTIPLE MYELOMA PATIENTS FROM A TERTIARY CARE HOSPITAL IN CHINA: A CROSS-SECTIONAL SURVEY STUDY
Mar 18, 2026, 21:38 PM -
REAL-WORLD TREATMENT PATTERNS IN COMMERCIALLY INSURED PATIENTS WITH RECURRENT OR PROGRESSIVE ENDOMETRIAL CANCER (EC) IN THE USA
Mar 18, 2026, 21:38 PM -
DOES ARTIFICIAL INTELLIGENCE IMPROVE OUTCOMES IN ACUTE ISCHEMIC STROKE CARE?
Mar 18, 2026, 21:38 PM -
HARNESSING AGENTIC AI FOR COHORT IDENTIFICATION: A CASE STUDY IN CLL/SLL PATIENTS TREATED WITH BTK INHIBITORS AT A US ACADEMIC HEALTH SYSTEM
Mar 18, 2026, 21:38 PM -
A QUALITATIVE STUDY TO EXPLORE PATIENT PERSPECTIVES ON FUTURE GENE THERAPY FOR LIMB GIRDLE MUSCULAR DYSTROPHY (LGMD) SARCOGLYCANOPATHY SUBTYPES 2E/R4, 2D/R3, AND 2C/R5
Mar 18, 2026, 21:38 PM -
CONSENSUS ON BARRIERS AND UNMET NEEDS IN HEMOPHILIA CARE IN BRAZIL: A MODIFIED DELPHI STUDY
Mar 18, 2026, 21:38 PM -
ECONOMIC VALUE OF RSV MATERNAL VACCINATION TO PREVENT INFANT DISEASE IN ECUADOR
Mar 18, 2026, 21:38 PM -
GLOBAL REGULATORY ASYMMETRIES AND THE STRUCTURAL DRUG LAG: TIME TO MARKET AUTHORIZATION IN CÔTE D’IVOIRE
Mar 18, 2026, 21:38 PM
